KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Debt to Equity (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Debt to Equity readings, the most recent being $2.02 for Q1 2026.

  • On a quarterly basis, Debt to Equity fell 23.92% to $2.02 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.02, a 23.92% decrease, with the full-year FY2025 number at $2.12, down 35.75% from a year prior.
  • Debt to Equity hit $2.02 in Q1 2026 for Teva Pharmaceutical Industries, down from $2.12 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $3.31 in Q4 2024 to a low of $2.02 in Q1 2026.
  • Median Debt to Equity over the past 5 years was $2.47 (2022), compared with a mean of $2.52.
  • Biggest five-year swings in Debt to Equity: soared 35.43% in 2024 and later crashed 35.75% in 2025.
  • Teva Pharmaceutical Industries' Debt to Equity stood at $2.47 in 2022, then fell by 1.07% to $2.44 in 2023, then soared by 35.43% to $3.31 in 2024, then crashed by 35.75% to $2.12 in 2025, then decreased by 4.84% to $2.02 in 2026.
  • The last three reported values for Debt to Equity were $2.02 (Q1 2026), $2.12 (Q4 2025), and $2.32 (Q3 2025) per Business Quant data.